Enlivex announces interim efficacy data from Phase I Allocetra trial

Enlivex Therapeutics (ENLV) announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis. The multi-center Phase I/II clinical trial consists of two stages. The first stage, which was successfully completed, was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the target knee in order to identify the dose and injection regimen for the subsequent Phase II stage. The interim efficacy results are highly positive, statistically significant, and show marked improvements in all key efficacy endpoints, including reduction of pain and an improvement in functionality, compared to baseline